

Dezocine can Alleviate Depression of Breast Cancer

Xu-Dong Hu, Kai Yang and Xianjie Wen*

Department of anesthesiology The Second People's Hospital of Foshan, Foshan 528000, China

***Corresponding author:** Xianjie Wen MD, Department of anesthesiology, The Second People's Hospital of Foshan, NO.78 of Weiguo Road, Chancheng District, Foshan Guangdong Province China 528000

Received: September 01, 2023

Published: January 24, 2024

To the editor,

Breast cancer is a common tumor in women in the world and more likely to concurrent depression with the incidence of 38.2%-44.2%. Depression can the decline of the quality of life of patients and their families, decrease the compliance to cancer treatment, and even directly lead to suicide. Sufentanil and dezocine were widely used in postoperative analgesia with the comparable analgesia effects. But the effects of both on depression in breast cancer surgery patients is not clear. A total of 80 patients in the Second People's Hospital of Foshan of Guangdong Province who received patient-controlled intravenous analgesia with dezocine 1.5mg/kg or sufentanil 1.5µg/kg were divide into DE group and SF group respectively, with 40 cases in each group. All patients underwent modified radical mastectomy under general anesthesia. There was no statistical difference of VAS scores at 24h and 48h after surgery between the two groups (All $P > 0.05$). The HAMD scores at 24h and 48h after surgery in DE group were significantly lower than those in SF group (All $P < 0.05$).

Our study found that dezocine was comparable to sufentanil in terms of the overall analgesic effect. Therefore, our study excluded the effect of pain on depression. We also found dezocine could reduce the HAMD scores of patients undergoing breast cancer surgery more effectively, compared with sufentanil. Zhao Peng et al. found that patients with dezocine + sufentanil had the lower Beck depression scores and anxiety scores, and better sleep quality than sufentanil alone which indirectly indicating the antidepressant effect of dezocine [1].

As we known 5-HT and/or NA reuptake inhibitors such as Duloxetine have been widely used to treat depression [2]. And the

KOR antagonists such buprenorphine [3] also have shown efficacy in the treatment of anxiety and depression. Dezocine is a 5-HT and NA reuptake inhibitor and a partial κ receptor agonist, which may have great potential for antidepressant effects [4]. Meanwhile, the antidepressant effect of dezocine has also been confirmed in a mouse models, which is associated with κ receptor and 5-HT_{1A} [5]. Our clinical studies have preliminarily confirmed this result in breast cancer patient undergoing surgery.

Keywords: Breast Cancer; Dezocine; Sufentanil; Depression

Conflict of interests: There are no conflicts of interest to declare

References

1. Zhao P, Wu Z, Li C, et al. Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: A randomized, controlled, double-blind trial. *PLoS One*, 2020; 15(5): e0233412.
2. Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanás T. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. *Front Psychiatry*, 2020; 11: 554899.
3. Khan MIH, Sawyer BJ, Akins NS, Le HV. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse. *Eur J Med Chem*, 2022; 243: 114785.
4. Liu R, Huang XP, Yeliseev A, Xi J, Roth BL. Novel molecular targets of dezocine and their clinical implications. *Anesthesiology*, 2014; 120(3): 714-723.
5. Shang L, Duan C, Chang S, Chang N, Jia S. Antidepressant-like effects of dezocine in mice: involvement of 5-HT_{1A} and κ opioid receptors. *Behav Pharmacol*, 2021; 32(6): 472-478.